

Serbia

Population 2018

8.8 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	1.5 (1.3–1.8)	17 (15–20)
HIV-positive TB incidence	<0.01 (<0.01–<0.01)	0.06 (0.03–0.09)
MDR/RR-TB incidence ^{oo}	0.022 (0.01–0.039)	0.25 (0.11–0.45)
HIV-negative TB mortality	0.055 (0.05–0.061)	0.63 (0.57–0.69)
HIV-positive TB mortality	0 (0–<0.01)	0.01 (0–0.02)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.1% (0.49–2.2)
Previously treated cases	4.7% (1.3–11)

TB case notifications, 2018

Total new and relapse	1 330
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	4%
- % pulmonary	81%
- % bacteriologically confirmed ^{ooo}	72%
- % children aged 0-14 years	2%
- % women	45%
- % men	53%
Total cases notified	1 358

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
--	--------------

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018	4% (3–4)
--	----------

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	8	14%
- on antiretroviral therapy	8	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	56%
- Previously treated cases	40%
Laboratory-confirmed cases*	MDR/RR-TB: 3, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 1, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	86%	1 440
Previously treated cases, excluding relapse, registered in 2017	56%	18
HIV-positive TB cases registered in 2017	75%	8
MDR/RR-TB cases started on second-line treatment in 2016	70%	10
XDR-TB cases started on second-line treatment in 2016	0%	1

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US\$ millions)	8.2
Funding source: 99% domestic, 0% international, 1% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females
■ Males
 Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive
■ MDR/RR-TB
■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically